



Product Information

HOE-140

Product Number **H-157**

Storage Temperature $-20\text{ }^{\circ}\text{C}$

Cas #: 138614-30-9

Synonyms: $\text{H}_2\text{N-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH}$; D-Arginyl-L-arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-($2\alpha,3\beta,7\alpha\beta$)-octahydro-1H-indole-2-carbonyl-L-arginine

Product Description

Mol. Formula: $\text{C}_{59}\text{H}_{89}\text{N}_{19}\text{O}_{13}\text{S}$

MW: 1304.6 (peptide free base)

Synthetic

White powder

Purity: $>90\%$ by HPLC

Peptide content: approx. 60%; remainder is salt and water of hydration.

HOE 140 is a selective B_2 bradykinin receptor antagonist. There are two known receptors for bradykinin, both of which are G-protein linked. The B_2 receptor is constitutively expressed on most cell types, while B_1 receptors are induced in response to inflammation, tissue damage or bacterial infection. The B_2 receptor appears to be involved in normal cardiovascular regulation and preservation of cardiac structure. B_2 antagonists increase heart rate and blood pressure. B_2 knockout mice develop cardiomyopathy. B_2 agonists are potent pain inducers and have pro-inflammatory activity. HOE-140 has been shown to have analgesic and anti-inflammatory effects in some models.

Preparation Instructions

Allow HOE 140 to come to room temperature in a desiccator prior to opening the container. Dissolve the peptide at 1 mg/ml in distilled water. The solution may be sonicated briefly to aid in solubilization. Buffer or saline should be added only after the peptide is fully in solution. Solutions should be stored at pH 5-7 in single-use aliquots at $-20\text{ }^{\circ}\text{C}$.

Storage/Stability

Store tightly sealed at $-20\text{ }^{\circ}\text{C}$.

References

Bock, M.G., and Longmore, J., Bradykinin antagonists: new opportunities. *Curr. Opin. Chem. Biol.*, **4**, 401-406 (2000).

Levy, D., and Zochodne, D.W., Increased mRNA expression of the B_1 and B_2 bradykinin receptors and antinociceptive effects of their antagonists in an animal model of neuropathic pain. *Pain*, **86**, 265-271 (2000).

Poole, S., et al., Bradykinin B_1 and B_2 receptors, tumour necrosis factor alpha and inflammatory hyperalgesia. *Br. J. Pharmacol.*, **126**, 649-656 (1999).

Feletou, M. et al., Agonistic and antagonistic properties of the bradykinin B_2 receptor antagonist, HOE 140, in isolated blood vessels from different species. *Br. J. Pharmacol.*, **112**, 683-689 (1994).

Wirth, K., et al., Hoe 140, a new potent and long acting bradykinin antagonist: *In vivo* studies. *Br. J. Pharmacol.*, **102**, 774-777 (1991).

Trifilieff, A., et al., Effect of HOE 140, a new B_2 noncompetitive antagonist, on guinea pig tracheal bradykinin receptors. *J. Pharmacol. Exp. Ther.*, **263**, 1377-1382 (1992).

Nossaman, B.D., et al., Analysis of responses to bradykinin and influence of HOE 140 in the isolated perfused rat lung. *Am. J. Physiol.* **266**, H2452-H2461 (1994).

LMY 5/15/01

Sigma brand products are sold through Sigma-Aldrich, Inc.

Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip.